FDA Approves Dupixent for Allergic Fungal Rhinosinusitis

Follow Drugslib on

By Lori Solomon HealthDay Reporter

Medically reviewed by Drugs.com

via HealthDay

THURSDAY, Feb. 26, 2026 -- The U.S. Food and Drug Administration has approved Dupixent (dupilumab) for the treatment of adult and pediatric patients aged 6 years and older with allergic fungal rhinosinusitis (AFRS) and a history of sino-nasal surgery.

Dupixent received priority review for AFRS, because AFRS may not respond well to available options. Current standard-of-care treatment includes surgery and prolonged courses of systemic steroids, with disease recurrence not uncommon.

The approval was based on the LIBERTY-AFRS-AIMS phase 3 trial, in which 62 participants with AFRS were randomly assigned to receive an age- and weight-based dose of Dupixent (200 mg or 300 mg) every two or four weeks (33 participants) or placebo (29 participants). Sinus opacification, assessed by computed tomography scans, improved by 50 percent with Dupixent compared with 10 percent with placebo at week 52, as well as week 24. Additionally, patient-reported nasal congestion/obstruction improved by 67 percent versus 25 percent at week 24, with continued improvement at week 52 (81 versus 11 percent). At both week 24 and week 52, nasal polyp size (assessed by endoscopy) was reduced by 61 versus 15 percent and 63 versus 4 percent, respectively. Other benefits included reductions in patient-reported loss of smell (67 versus 19 percent at week 24) and reduced treatment burden (92 percent reduction in the risk for systemic corticosteroid use and/or need of surgery).

"Beyond reducing nasal signs and symptoms, Dupixent reduced the need for surgery or systemic corticosteroids, with fewer patients having bone erosion in the sinuses," George D. Yancopoulos, M.D., Ph.D., president and chief scientific officer at Regeneron, said in a statement. "These results underscore its potential to establish a new standard of care for people living with AFRS."

This approval of Dupixent was granted to Regeneron.

More Information

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

Source: HealthDay

Posted : 2026-02-27 08:46

Read more

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Popular Keywords